一例复发性转移性腮腺腺样囊性癌对帕博利珠单抗有反应。
A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab.
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
出版信息
In Vivo. 2022 Mar-Apr;36(2):1047-1051. doi: 10.21873/invivo.12801.
BACKGROUND
No clear chemotherapy regimen for recurrent or metastatic parotid cancer exists. We describe our experience with pembrolizumab to treat recurrent or metastatic parotid cancer.
CASE REPORT
A 73-year-old woman with swelling in the lower part of the right ear for 10 years before surgery was diagnosed with right parotid cancer, underwent total right parotidectomy, and reported recurrence. She requested treatment due to diminished quality of life caused by neurological symptoms. Tissue was collected from the recurrent lesion and its combined positive score was >20; pembrolizumab was started 9 years postoperatively.
RESULTS
To date, the patient has received 14 cycles of pembrolizumab. Evaluation by computed tomography showed a partial response to treatment. The only immune-related adverse event was grade 1 pneumonia in both lungs.
CONCLUSION
Significant response to pembrolizumab in recurrent or metastatic parotid cancer is rarely reported, making this a remarkable case. We plan to continue pembrolizumab administration.
背景
复发性或转移性腮腺癌目前尚无明确的化疗方案。我们描述了使用派姆单抗治疗复发性或转移性腮腺癌的经验。
病例报告
一名 73 岁女性，手术前右耳下部肿胀 10 年，诊断为右腮腺癌，行全腮腺切除术，并报告复发。由于神经症状导致生活质量下降，她要求治疗。从复发病灶采集组织，其综合阳性评分>20；术后 9 年开始使用派姆单抗。
结果
迄今为止，患者已接受了 14 个周期的派姆单抗治疗。计算机断层扫描评估显示治疗有部分缓解。唯一的免疫相关不良事件是双侧肺炎 1 级。
结论
复发性或转移性腮腺癌对派姆单抗有显著反应的报道很少见，因此这是一个显著的病例。我们计划继续派姆单抗治疗。
Zotero 插件